- Email: [email protected]
or COPD
Abstracts S281
1021
Use of Beta Blockers in Congestive Heart Failure Patients With Asthma and/or COPD
P. L. G. Dinger1, J. Peters2, A. D. Galbreath3, P. B. Smith3, G. L. Freeman4; 1Internal Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, 2Pulmonology, University of Texas Health Science Center San Antonio, San Antonio, TX, 3Disease Management Center, UTHSCSA/ALMVAH, San Antonio, TX, 4Cardiology, University of Texas Health Science Center San Antonio, San Antonio, TX. RATIONALE: To determine the prevalence of beta adrenergic blocking agent usage in patients with a diagnosis of both asthma or COPD and congestive heart failure (CHF). METHODS: We reviewed baseline data from 1061 patients with CHF evaluated in a community based study of disease management. Self reported asthma on verbally administered questionnaire at the initial visit was found in 63/1061 (5.9%) of the patients. COPD was reported by 119/1061 (11.2%), and both asthma and COPD was reported in 27/1061 (30% of asthma patients reported both). RESULTS: Less than half (28/63 or 44.5%) of asthmatics with CHF were on β-blockers. Of those on β-blockers, 53.6% were placed on cardioselective β-blockers. Of the patients with COPD alone 32.0% (38/119) were on β-blockers, of which only 47.4% were cardioselective. In patients with both asthma and COPD, 33.4% (9/27) were on β-blockers, 44.4% of which were cardioselective. CONCLUSIONS: Although a history of asthma and/or COPD is considered a relative contraindication to the use of β-blockers in the management of CHF, the proven mortality benefit of these drugs mandates their use when possible in these conditions. We found that they are routinely prescribed by physicians in the community for both asthma and COPD, more frequently in asthma. Cardioselective β-blockers are the β-adrendergic blocking medication of choice in roughly half of patients with obstructive lung disease, more frequently prescribed in patients with asthma. Further assessment of outcomes in these patients will provide insight into how best to address this common and important clinical dilemma. Funding: Self-funded
TUESDAY
J ALLERGY CLIN IMMUNOL VOLUME 113, NUMBER 2
1021
Use of Beta Blockers in Congestive Heart Failure Patients With Asthma and/or COPD
P. L. G. Dinger1, J. Peters2, A. D. Galbreath3, P. B. Smith3, G. L. Freeman4; 1Internal Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, 2Pulmonology, University of Texas Health Science Center San Antonio, San Antonio, TX, 3Disease Management Center, UTHSCSA/ALMVAH, San Antonio, TX, 4Cardiology, University of Texas Health Science Center San Antonio, San Antonio, TX. RATIONALE: To determine the prevalence of beta adrenergic blocking agent usage in patients with a diagnosis of both asthma or COPD and congestive heart failure (CHF). METHODS: We reviewed baseline data from 1061 patients with CHF evaluated in a community based study of disease management. Self reported asthma on verbally administered questionnaire at the initial visit was found in 63/1061 (5.9%) of the patients. COPD was reported by 119/1061 (11.2%), and both asthma and COPD was reported in 27/1061 (30% of asthma patients reported both). RESULTS: Less than half (28/63 or 44.5%) of asthmatics with CHF were on β-blockers. Of those on β-blockers, 53.6% were placed on cardioselective β-blockers. Of the patients with COPD alone 32.0% (38/119) were on β-blockers, of which only 47.4% were cardioselective. In patients with both asthma and COPD, 33.4% (9/27) were on β-blockers, 44.4% of which were cardioselective. CONCLUSIONS: Although a history of asthma and/or COPD is considered a relative contraindication to the use of β-blockers in the management of CHF, the proven mortality benefit of these drugs mandates their use when possible in these conditions. We found that they are routinely prescribed by physicians in the community for both asthma and COPD, more frequently in asthma. Cardioselective β-blockers are the β-adrendergic blocking medication of choice in roughly half of patients with obstructive lung disease, more frequently prescribed in patients with asthma. Further assessment of outcomes in these patients will provide insight into how best to address this common and important clinical dilemma. Funding: Self-funded
TUESDAY
J ALLERGY CLIN IMMUNOL VOLUME 113, NUMBER 2